Mangoceuticals (MGRX) Consolidated Net Income (2023 - 2026)

Mangoceuticals (MGRX) has 4 years of Consolidated Net Income data on file, last reported at -$3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 29.68% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at -$19.2 million (down 71.81% YoY), and the FY2025 full-year result was -$16.3 million, down 137.08% from the prior year.
• Consolidated Net Income declined to -$3.4 million in Q1 2026, from -$2.8 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$1.8 million in Q3 2023 to a low of -$7.6 million in Q3 2025.
• A 4-year average of -$3.2 million and a median of -$2.6 million in 2023 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income tumbled 281.0% in 2025 and grew 29.68% in 2026, its largest moves.
• Tracing MGRX's Consolidated Net Income over 4 years: stood at -$2.6 million in 2023, then advanced by 24.12% to -$1.9 million in 2024, then plunged by 42.12% to -$2.8 million in 2025, then decreased by 22.89% to -$3.4 million in 2026.
• Business Quant data shows MGRX's Consolidated Net Income at -$3.4 million in Q1 2026, -$2.8 million in Q4 2025, and -$7.6 million in Q3 2025.